Thus, higher expression of HER-2/neu in prostatic tumors with high Gleason scores may cause a more intense downregulation of MHC Class I antigens, accompanied by lower frequencies of HER-2/neu peptide-specific CD8+ T cells at similar levels to those detected in prostatic tumors with a low Gleason score. This evidence concerns the gene ERBB2 and prostate neoplasm.